Track topics on Twitter Track topics that are important to you
Boston Scientific Paclitaxel Eluting Self Expanding Stent System PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Boston Scientific Paclitaxel Eluting Self Expanding Stent System articles that have been published worldwide.
We have published hundreds of Boston Scientific Paclitaxel Eluting Self Expanding Stent System news stories on BioPortfolio along with dozens of Boston Scientific Paclitaxel Eluting Self Expanding Stent System Clinical Trials and PubMed Articles about Boston Scientific Paclitaxel Eluting Self Expanding Stent System for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Boston Scientific Paclitaxel Eluting Self Expanding Stent System Companies in our database. You can also find out about relevant Boston Scientific Paclitaxel Eluting Self Expanding Stent System Drugs and Medications on this site too.
The optimal treatment of in-stent restenosis (ISR) remains unknown. This study evaluates the efficacy and safety of a paclitaxel coated balloon compared to a 2nd generation sirolimus eluting stent in patients with ISR in bare metal stents (BMS) or drug eluting stents (DES).
The clinical performance of the SYNERGY drug-eluting stent (DES) in patients with acute myocardial infarction (MI) has not been investigated in detail. We sought to report on the outcomes after SYNERGY DES (Boston Scientific, Marlborough, MA, USA) implantation in patients with MI undergoing percutaneous revascularisation (PCI).
Antithrombotic management after percutaneous coronary intervention is based on dual antiplatelet therapy (DAPT), that has unequivocally shown to reduce the risk of recurrent ischemic events at cost of an important risk of bleeding. In order to balance ischemic and bleeding risks, DAPT duration should be based on patients and lesions features as well as stent type. Based on these considerations, patients at high bleeding risk (HBR) undergoing PCI represent a challenging subgroup. The Synergy stent (Boston Sc...
Coronary drug-eluting stent development has introduced new metal alloys, changes in stent architecture and bioresorbable polymers. Whether these advancements improve long-term clinical safety and efficacy has been inconsistent in prior studies.
In this substudy of the SORT OUT VII trial, the clinical outcomes among patient with diabetes mellitus treated with Orsiro sirolimus-eluting stent (O-SES; Biotronik, Bülach, Switzerland) or Nobori biolimus-eluting stent (N-BES; Terumo, Tokyo, Japan) were compared.
Intracranial atherosclerotic disease is a well-known cause of ischemic stroke. Following the SAMMPRIS trial, medical treatment is favored over stenting. Drug-eluting balloons (DEB) are widely used in coronary angioplasty, showing better results than bare-surface balloons. There is little evidence of DEB employment in intracranial stenosis, especially of paclitaxel-eluted balloons (pDEB). The Neuro Elutax SV (Aachen Resonance) is the first CE certificated pDEB for intracranial use.
Endothelial progenitor cells (EPCs) may allow accelerated and functional endothelialization of stents, theoretically reducing late stent complications as well reducing the duration of DAPT. In a pilot study of 193 patients at high risk of target vessel failure (TVF), the Genous EPC capturing stent (ESC) and TAXUS Liberté paclitaxel-eluting second-generation stent (PES) were similar at 5-years. Events rates appear higher for ESC within the first-year followed by higher rate of complications for PES during y...
A 43-year-old woman with advanced gastric cancer was presented with gastric outlet obstruction. Duodenal stent (WallFlex duodenal soft 22mm x 12cm, Boston Scientific, Japan) was deployed to cover the stricture between antrum and 2 part of duodenum. The stent did not expand fully because of the tight stricture even after balloon dilation. The stent became longer than expected which caused the kinking at the stomach (Figure 1). This article is protected by copyright. All rights reserved.
Stent technology has rapidly evolved since the first stainless steel bare metal stents with substantial developments in scaffolding, polymer, drug choice, drug delivery, and elution mechanisms. Most recently, there has been the evolution of bioabsorbable vascular scaffolds, potentially eliminating the need for long-term foreign object retention. These rapid developments have led to an ever-expanding selection of new stents, making the choice of which to use in which patient challenging. Operators must balan...
The MASTER study was designed to compare performance of a new biode-gradable polymer sirolimus-eluting stent (BP-SES) with a bare-metal stent (BMS) in patients with ST-segment elevation myocardial infarction (STEMI).
To assess the efficacy and safety of the Xience Prime everolimus-eluting stent (EES) in long coronary lesions in a real-world population.
The aim of this study was to investigate whether the underlying plaque type affects the neointimal coverage after drug-eluting stent implantation.
Drug eluting stents are one of the main devices of coronary intervention, which play a therapeutic role through the combination of medical devices. Drug is an important part of the drug eluting stents. The loading method, the type of carrier, drug and carrier interaction and the preparation process of the drug directly affect the drugs release kinetics characteristics of the device and the final treatment. According to the characteristics of the drug coating, drug coated stents can be divided into non-degra...
It is unclear whether the obesity paradox is still apparent in the new-generation drug-eluting stent (DES) era. Therefore, we assessed the impact of body mass index (BMI) on clinical outcome after percutaneous coronary intervention (PCI) with new-generation DESs.
Drug-eluting stent (DES) strut fracture (SF) is associated with higher incidence of In-stent restenosis (ISR)-return of blockage in a diseased artery post stenting-than seen with bare metal stents (BMS). We hypothesize that concomitance of drug and SF leads to greater neointimal response.
Previous intravascular ultrasound studies suggested the association of stent underexpansion with increased risk of stent thrombosis and restenosis. However, no previous study has addressed the association of the suboptimal angiographic result with target-lesion revascularization (TLR) in patients receiving new-generation drug-eluting stents (DES).
The aim of this study was to provide contemporary outcome data for patients with de novo coronary disease and Medina 1,1,1 lesions who were treated with a culotte two-stent technique, and to compare the performance of two modern-generation drug-eluting stent (DES) platforms, the 3-connector XIENCE and the 2-connector SYNERGY.
The current guidelines from the European Society of Cardiology and European Society of Anaesthesiology on non-cardiac surgery (ESC/ESA-NCS) divide surgical procedures into those associated with low (5%) of major adverse cardiac events (MACE). Evaluating surgical risk might be particularly appropriate in patients with recent stent implantation and thus we validated the ESC/ESA-NCS classification in patients undergoing NCS within 1 year after coronary drug-eluting stent (DES) implantation.
Use of a BRS either in clinical practice or in the setting of an acute myocardial infarction (MI) is controversial. Despite an overall high rate of thrombosis, vascular healing response following BRS implantation tend to superiority as compared to metallic drug-eluting stent in ST-segment elevation myocardial infarction (STEMI) patients. We sought to compare the in-stent/scaffold vasomotion between metallic bioresorbable scaffold (BRS) and sirolimus eluting stent (SES) at 12-month angiographic follow-up in ...
Intravascular ultrasound (IVUS)-guided drug-eluting stent (DES) implantation is associated with less major adverse cardiovascular events (MACE) compared with angiography guidance for patients with individual lesion subset. However, the beneficiary effect on MACE outcome of IVUS guidance over angiography guidance in all-comers who undergo DES implantation still remains understudied.
It remains controversial whether coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) should be optimized to treat coronary artery disease in patients on chronic hemodialysis (HD). Recently, further refinement of drug-eluting stents, such as the everolimus-eluting stent (EES), has led to marked development in this field. We compared long-term clinical outcomes after CABG versus PCI with EES implantation in patients on chronic HD.
The authors sought to investigate the association between P2Y reaction units (PRU) and the risk of ischemic stroke (IS) after successful coronary drug-eluting stents (DES) implantation.
Early-generation drug-eluting stents (DES) have been shown to accelerate neoatherogenesis. Limited optical coherence tomography (OCT) data on the very long-term neoatherosclerosis progression after DES implantation are available.
This work aims to investigate the effects of plaque eccentricity and composition on the stent performance and stress distributions of plaque and artery during stenting by the finite element method. Three-dimensional stent-plaque-artery models for plaques with five different eccentricities and four different compositions were simulated, and the influences on stent recoil, stent plastic strain, stent foreshortening, stress distributions of artery and plaque, and lumen gain were studied. The results show that ...